TY - JOUR
T1 - Current Challenges in Vaccinology
AU - Kennedy, Richard B.
AU - Ovsyannikova, Inna G.
AU - Palese, Peter
AU - Poland, Gregory A.
N1 - Funding Information:
We thank Caroline L. Vitse for editorial assistance. Funding. Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award numbers U01AI089859, R01AI132348, R37AI048793, R01AI033144, R01AI121054, R01AI138965, R01AI127365, 75N93019C00052 (NIAID), R01AI145870, 75N93019C0051, P01AI097092, and 75D30119C06088 (Centers for Disease Control and Prevention). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Publisher Copyright:
© Copyright © 2020 Kennedy, Ovsyannikova, Palese and Poland.
PY - 2020/6/25
Y1 - 2020/6/25
N2 - The development of vaccines, which prime the immune system to respond to future infections, has led to global declines in morbidity and mortality from dreadful infectious communicable diseases. However, many pathogens of public health importance are highly complex and/or rapidly evolving, posing unique challenges to vaccine development. Several of these challenges include an incomplete understanding of how immunity develops, host and pathogen genetic variability, and an increased societal skepticism regarding vaccine safety. In particular, new high-dimensional omics technologies, aided by bioinformatics, are driving new vaccine development (vaccinomics). Informed by recent insights into pathogen biology, host genetic diversity, and immunology, the increasing use of genomic approaches is leading to new models and understanding of host immune system responses that may provide solutions in the rapid development of novel vaccine candidates.
AB - The development of vaccines, which prime the immune system to respond to future infections, has led to global declines in morbidity and mortality from dreadful infectious communicable diseases. However, many pathogens of public health importance are highly complex and/or rapidly evolving, posing unique challenges to vaccine development. Several of these challenges include an incomplete understanding of how immunity develops, host and pathogen genetic variability, and an increased societal skepticism regarding vaccine safety. In particular, new high-dimensional omics technologies, aided by bioinformatics, are driving new vaccine development (vaccinomics). Informed by recent insights into pathogen biology, host genetic diversity, and immunology, the increasing use of genomic approaches is leading to new models and understanding of host immune system responses that may provide solutions in the rapid development of novel vaccine candidates.
KW - genetics
KW - genomics
KW - transcriptomics
KW - vaccine
KW - vaccine development
UR - http://www.scopus.com/inward/record.url?scp=85087738173&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087738173&partnerID=8YFLogxK
U2 - 10.3389/fimmu.2020.01181
DO - 10.3389/fimmu.2020.01181
M3 - Review article
C2 - 32670279
AN - SCOPUS:85087738173
SN - 1664-3224
VL - 11
JO - Frontiers in Immunology
JF - Frontiers in Immunology
M1 - 1181
ER -